Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products
in core European markets
LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, and Immedica Pharma AB, a pharmaceutical company focused on commercialisation of rare and specialty care products, today announce that the companies have entered an exclusive long-term license and distribution agreement for the commercialisation of two cancer supportive care products indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in core European markets: AKYNZEO® (Netupitant-Palonosetron fixed combination) and ALOXI® (Palonosetron). Under the licence and distribution agreement Immedica will commercialise AKYNZEO® in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg and Liechtenstein, ALOXI® in Switzerland, Belgium, Liechtenstein.
Anders Edvell, CEO of Immedica commented: “We are very pleased to have signed this agreement with Helsinn. Side-effects of cancer treatments have a significant impact on the quality of life of these severely ill patients. AKYNZEO® and ALOXI® are also an important addition to Immedica’s Oncology & Haematology portfolio.”
Dr. Melanie Rolli, Helsinn Group CEO, commented: “This partnership will provide important treatment options for CINV across Europe. We look forward to working closely with Immedica in the months and years ahead to ensure more and more patients can access these important supportive care products.”
About AKYNZEO®
AKYNZEO® is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.
AKYNZEO® is currently registered and available in more than 60 Countries
About ALOXI®
ALOXI® is approved in Europe in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. ALOXI® is also indicated in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
ALOXI® is currently registered and available in more than 40 Countries.
About Immedica Pharma
Immedica is a fast-growing private niche pharma group, headquartered in Stockholm, Sweden
with commercial coverage across Europe and the Middle East.
Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality, and product distribution.
Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 10 billion in committed capital from leading Nordic and international investors.
For more information visit www.immedica.com.
About Helsinn
Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases.
Helsinn is a third-generation family-owned company, that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. Helsinn’s unique business model enables it to in-license or acquire assets at a late stage of development. It has a commercial presence in 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its network of long-standing trusted partners. Helsinn also has a fully integrated supply chain and product development through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd.
Helsinn plays an active and central role in promoting social transformation in favor of people and the environment. Sustainability is at the heart of everything we do, which is reinforced in the company’s strategic plan by a commitment to sustainable growth.
To learn more about Helsinn please visit: www.helsinn.com
For more information:
Immedica
Linda Holmström
Head of Communication
e-mail: linda.holmstrom@immedica.com
Phone: + 46 708 73 40 95
Helsinn Group Media Contact:
Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Email: Info-hhc@helsinn.com
For more information, please visit www.helsinn.com and follow us on Twitter andLinkedIn
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab25.4.2024 04:11:25 CEST | Press release
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region (“DO”) has recently accepted the New Drug Application (“NDA”) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (“NPC”), and as a single agent for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational multi-center Phase 3 clinical study (NCT03581786) that examined toripalimab in combina
Net Income of R$ 55.3 mm in 1Q24, a 90.1% Increase YOY and Leases EBITDA Margin of 72.1%25.4.2024 02:58:18 CEST | Press release
On track to deliver 2024 Record Production of 500,000 sqm of GLA BELO HORIZONTE, Brazil, April 24, 2024 (GLOBE NEWSWIRE) -- Log Commercial Properties (B3: LOGG3), a leading developer of greenfield assets and lessor of Class A logistics warehouses in Brazil, is pleased to announce its financial results for the first quarter. 1Q24 Operational Highlights: Deliveries totaling 57,000 sqm of GLA were completed with a 100% pre-lease rateMilestone of 2.0 million sqm of GLA historically delivered by the CompanyGross absorption of 134,000 sqm of GLAStabilized vacancy of 0.91%,Same Client Rent of 1,9%, above inflation for the 7th consecutive quarter 1Q24 Financial Highlights: Strong EBITDA of R$ 74.0 million in 1Q24, with a growth of 36.4%EBITDA from leases of R$ 38.8 million and a margin of 72.1% in 1Q24Asset recycling of R$ 1.7 billion in the last 12 monthsAdjusted net debt reduction of 37.4%, totaling R$ 744.3 million in 1Q24Adjusted leverage of 0.8x considering the asset sales in April Manage
Elavon and FreedomPay to transform payments for hospitality and retail in Europe25.4.2024 01:01:00 CEST | Press release
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Elavon, a leading global payments provider, today announces its expanded collaboration in Europe with FreedomPay, a global leader in Next Level Commerce™ technologies. The partnership aims to deliver cutting-edge integrated commerce solutions and omni-channel payments technology to large enterprise merchants across Retail and Hospitality. The agreement pairs Elavon acquiring with FreedomPay commerce technologies to benefit Elavon merchants across Europe, empowering businesses with enhanced payment flexibility and optionality, data security, and a seamlessly integrated payments technology across both physical and ecommerce channels. “Elavon and FreedomPay have an enviable track record in Europe of helping hospitality and retail merchants grow their operations and better meet their customers’ needs,” said Hemlata Narasimhan, President of Elavon in Europe. “We’re pleased to extend our relationship with FreedomPay to continue to offer the first-cl
Ensurge Micropower ASA - Grant of Incentive Subscription Rights24.4.2024 23:30:00 CEST | Press release
The Board of Directors of Ensurge Micropower ASA (the "Company") resolved on 24 April 2024 to issue a total of 202,200 incentive subscription rights to employees in the Ensurge group. The grants were made under the Company's 2023 incentive subscription rights plan, as resolved at the Annual General Meeting on 24 May 2023, and amended on the Extraordinary General Meeting held on 10 November 2023. The exercise price of the subscription rights is calculated to NOK 1.2640 per share. The subscription rights expire on 24 May 2028. The subscription rights follow the terms and conditions of the 2023 subscription rights incentive plan. Following the grant there are 46,057,881 incentive subscription rights issued and outstanding in the Company. For more information, please contact: Lars Eikeland, Chief Executive Officer E- mail: lars.eikeland@ensurge.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Bombardier Unveils Bold New Brand Identity Worldwide as Company Soars Toward an Ambitious Future24.4.2024 23:12:07 CEST | Press release
A new logo celebrates the company’s successful shift toward pure-play business aviation. The symbol itself, the Bombardier Mach, features the silhouette of an aircraft breaking the sound barrier, while the strokes of wind over a wing reference the company’s heritageThe employee value proposition “where heart meets mastery” focuses on Bombardier’s talented people, celebrating the workforce’s renowned passion, its incredible craftsmanship and profound technological expertise MONTRÉAL, April 24, 2024 (GLOBE NEWSWIRE) -- Bombardier, the worldwide leader in business aviation, today unveiled a new brand identity anchored by the evolution of the company’s logo. As Bombardier successfully moves forward as a company with a sole focus on designing, building and servicing the world’s best business jets, the new brand identity will reinforce and propel the company’s unique approach to its customers and stakeholders—putting people at the centre and instilling a one-of-a-kind sense of family. Bombar